Ondansetron-d5
CAT:
804-HY-B0002BS
Size:
1 mg
For Laboratory Research Only. Not for Clinical or Personal Use.
Price:
Ask
- Availability: 24/48H Stock Items & 2 to 6 Weeks non Stock Items.
- Dry Ice Shipment: No


Ondansetron-d5
Description:
Ondansetron-d5 is the deuterium labeled Ondansetron (HY-B0002B) . Ondansetron (GR 38032; SN 307) is a highly selective 5-HT3 receptor antagonist with an IC50 value of 103 pM. Ondansetron exerts its antiemetic effect by antagonizing 5-HT receptors located in localized neurons in the peripheral and central nervous systems. Ondansetron can inhibit nausea and vomiting induced by chemotherapy and radiotherapy[1][2][3][4][5][6][7][8].Product Name Alternative:
GR 38032-d5; SN 307-d5UNSPSC:
12352005Target:
5-HT Receptor; Isotope-Labeled CompoundsType:
Isotope-Labeled CompoundsRelated Pathways:
GPCR/G Protein; Neuronal Signaling; OthersField of Research:
Neurological DiseasePurity:
99.0Solubility:
10 mM in DMSO|DMSO : 10mg/mL (ultrasonic)Smiles:
O=C1C(CN2C([2H])=C([2H])N=C2C([2H])([2H])[2H])CCC(N3C)=C1C4=C3C=CC=C4Molecular Formula:
C18H14D5N3OMolecular Weight:
298.39References & Citations:
[1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53 (2) :211-216. |[2]Brown AM, et al. Ion permeation and conduction in a human recombinant 5-HT3 receptor subunit (h5-HT3A) . J Physiol. 1998 Mar 15;507 (Pt 3) :653-65.|[3]Barann M, et al. Recombinant human 5-HT3A receptors in outside-out patches of HEK 293 cells: basic properties and barbiturate effects. Naunyn Schmiedebergs Arch Pharmacol. 2000 Sep;362 (3) :255-65.|[4]Wildeboer KM, et al. Ondansetron results in improved auditory gating in DBA/2 mice through a cholinergic mechanism. Brain Res. 2009 Dec 1;1300:41-50.|[5]Khedhaier A, et al. Circadian rhythms in toxic effects of the serotonin antagonist ondansetron in mice. Chronobiol Int. 2003 Nov;20 (6) :1103-16.|[6]Umathe SN, et al. The 5-HT3 receptor antagonist, ondansetron, blocks the development and expression of ethanol-induced locomotor sensitization in mice. Behav Pharmacol. 2009 Feb;20 (1) :78-83.|[7]Doggrell SA, et al. Cardiac safety concerns for ondansetron, an antiemetic commonly used for nausea linked to cancer treatment and following anaesthesia. Expert Opin Drug Saf. 2013 May;12 (3) :421-31.|[8]Xin Wang, et al. Effectiveness of Olanzapine Combined with Ondansetron in Prevention of Chemotherapy-Induced Nausea and Vomiting of Non-small Cell Lung Cancer. Cell Biochem Biophys. 2015 Jun;72 (2) :471-3.|[9]Azadeh Motavallian-Naeini, et al. Anti-inflammatory effect of ondansetron through 5-HT3 receptors on TNBS-induced colitis in rat. EXCLI J2012 Feb 22:11:30-44. eCollection 2012. |[10]허원석. Effects of ondansetron on the activity of glutamate transporter type 3 and the modulation mechanism[D]. 서울대학교 대학원, 2014.Shipping Conditions:
Room TemperatureStorage Conditions:
-20°C, 3 years; 4°C, 2 years (Powder)Scientific Category:
Isotope-Labeled CompoundsClinical Information:
No Development ReportedCAS Number:
1219798-86-3
